Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ

A. Noto, C. De Vitis, M. E. Pisanu, G. Roscilli, G. Ricci, A. Catizone, G. Sorrentino, G. Chianese, O. Taglialatela-Scafati, D. Trisciuoglio, D. Del Bufalo, M. Di Martile, A. Di Napoli, L. Ruco, S. Costantini, Z. Jakopin, A. Budillon, G. Melino, G. Del Sal, G. CilibertoR. Mancini

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.75.
Original languageEnglish
Pages (from-to)4671-4672
Number of pages2
JournalOncogene
Volume36
Issue number32
DOIs
Publication statusPublished - 2017

Fingerprint

Stearoyl-CoA Desaturase
Lung Neoplasms
beta Catenin
Proteins
Neoplastic Stem Cells
Axin Signaling Complex
Monounsaturated Fatty Acids
Primary Cell Culture
Computational Biology
Oncogenes
Publications
Cell Survival
Fatty Acids
Down-Regulation
Immunohistochemistry

Cite this

Noto, A., Vitis, C. D., Pisanu, M. E., Roscilli, G., Ricci, G., Catizone, A., ... Mancini, R. (2017). Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene, 36(32), 4671-4672. https://doi.org/10.1038/onc.2017.75 [doi]

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. / Noto, A.; Vitis, C. De; Pisanu, M. E.; Roscilli, G.; Ricci, G.; Catizone, A.; Sorrentino, G.; Chianese, G.; Taglialatela-Scafati, O.; Trisciuoglio, D.; Bufalo, D. Del; Martile, M. Di; Napoli, A. Di; Ruco, L.; Costantini, S.; Jakopin, Z.; Budillon, A.; Melino, G.; Sal, G. Del; Ciliberto, G.; Mancini, R.

In: Oncogene, Vol. 36, No. 32, 2017, p. 4671-4672.

Research output: Contribution to journalArticle

Noto, A, Vitis, CD, Pisanu, ME, Roscilli, G, Ricci, G, Catizone, A, Sorrentino, G, Chianese, G, Taglialatela-Scafati, O, Trisciuoglio, D, Bufalo, DD, Martile, MD, Napoli, AD, Ruco, L, Costantini, S, Jakopin, Z, Budillon, A, Melino, G, Sal, GD, Ciliberto, G & Mancini, R 2017, 'Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ', Oncogene, vol. 36, no. 32, pp. 4671-4672. https://doi.org/10.1038/onc.2017.75 [doi]
Noto, A. ; Vitis, C. De ; Pisanu, M. E. ; Roscilli, G. ; Ricci, G. ; Catizone, A. ; Sorrentino, G. ; Chianese, G. ; Taglialatela-Scafati, O. ; Trisciuoglio, D. ; Bufalo, D. Del ; Martile, M. Di ; Napoli, A. Di ; Ruco, L. ; Costantini, S. ; Jakopin, Z. ; Budillon, A. ; Melino, G. ; Sal, G. Del ; Ciliberto, G. ; Mancini, R. / Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. In: Oncogene. 2017 ; Vol. 36, No. 32. pp. 4671-4672.
@article{2546c15a807b4652a5f6697c8a9d2b2e,
title = "Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ",
abstract = "Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.75.",
author = "A. Noto and Vitis, {C. De} and Pisanu, {M. E.} and G. Roscilli and G. Ricci and A. Catizone and G. Sorrentino and G. Chianese and O. Taglialatela-Scafati and D. Trisciuoglio and Bufalo, {D. Del} and Martile, {M. Di} and Napoli, {A. Di} and L. Ruco and S. Costantini and Z. Jakopin and A. Budillon and G. Melino and Sal, {G. Del} and G. Ciliberto and R. Mancini",
note = "LR: 20170619; JID: 8711562; EIN: Oncogene. 2017 Jun 19;:. PMID: 28628115; 2016/08/29 [received]; 2017/02/03 [revised]; 2017/02/17 [accepted]; aheadofprint",
year = "2017",
doi = "10.1038/onc.2017.75 [doi]",
language = "English",
volume = "36",
pages = "4671--4672",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "32",

}

TY - JOUR

T1 - Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ

AU - Noto, A.

AU - Vitis, C. De

AU - Pisanu, M. E.

AU - Roscilli, G.

AU - Ricci, G.

AU - Catizone, A.

AU - Sorrentino, G.

AU - Chianese, G.

AU - Taglialatela-Scafati, O.

AU - Trisciuoglio, D.

AU - Bufalo, D. Del

AU - Martile, M. Di

AU - Napoli, A. Di

AU - Ruco, L.

AU - Costantini, S.

AU - Jakopin, Z.

AU - Budillon, A.

AU - Melino, G.

AU - Sal, G. Del

AU - Ciliberto, G.

AU - Mancini, R.

N1 - LR: 20170619; JID: 8711562; EIN: Oncogene. 2017 Jun 19;:. PMID: 28628115; 2016/08/29 [received]; 2017/02/03 [revised]; 2017/02/17 [accepted]; aheadofprint

PY - 2017

Y1 - 2017

N2 - Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.75.

AB - Recent evidences suggest that stearoyl-CoA-desaturase 1 (SCD1), the enzyme involved in monounsaturated fatty acids synthesis, has a role in several cancers. We previously demonstrated that SCD1 is important in lung cancer stem cells survival and propagation. In this article, we first show, using primary cell cultures from human lung adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), are required for the generation of lung cancer three-dimensional cultures and that SCD1 knock down and pharmacological inhibition both decrease expression, nuclear localization and transcriptional activity of YAP and TAZ. Regulation of YAP/TAZ by SCD1 is at least in part dependent upon beta-catenin pathway activity, as YAP/TAZ downregulation induced by SCD1 blockade can be rescued by the addition of exogenous wnt3a ligand. In addition, SCD1 activation of nuclear YAP/TAZ requires inactivation of the beta-catenin destruction complex. In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma samples showed that expression levels of SCD1 co-vary with those of beta-catenin and YAP/TAZ. Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, beta-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma. Finally, bioinformatics analyses directed to identify which gene combinations had synergistic effects on clinical outcome in lung cancer showed that poor survival is associated with high co-expression of SCD1, beta-catenin and the YAP/TAZ downstream target birc5. In summary, our data demonstrate for the first time the involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids metabolism as a key regulator of lung cancer stem cells.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.75.

U2 - 10.1038/onc.2017.75 [doi]

DO - 10.1038/onc.2017.75 [doi]

M3 - Article

VL - 36

SP - 4671

EP - 4672

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 32

ER -